findmyKOL
Clinical trialNCT02949219Active, not recruitingPhase 2Interventional

Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

SponsorAcademic and Community Cancer Research UnitedEnrollment41Metastatic Small Intestinal AdenocarcinomaRecurrent Small Intestinal CarcinomaUnresectable Small Intestinal Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic Hospital

    Phoenix, Arizona, United States

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, United States

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia, United States

  • Mayo Clinic

    Rochester, Minnesota, United States

  • Washington University School of Medicine

    St Louis, Missouri, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, United States

  • Rapid City Regional Hospital

    Rapid City, South Dakota, United States

  • M D Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
24 Mar 2017
Primary completion
31 Jan 2019
Completion
31 Dec 2024
Last update posted
22 Aug 2024
Registered enrollment
41
Registry id
NCT02949219

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.